“MDD is a prevalent and serious mood disorder affecting over 21 million adults in the United States. 1 This condition often leads to profound sadness, loss of interest in activities, and disruptions in daily life. Around one-third of people with MDD are resistant to current antidepressant therapies, highlighting the urgent need for new approaches. 2
“BHV-7000 targets potassium channels in the brain, which help regulate electrical activity. This novel mechanism is designed to stabilize overactive brain activity that contributes to depression. 3 Early clinical research has shown evidence of antidepressant activity and suggests that BHV-7000 may be better tolerated than existing options without the typical side effects of antidepressant medications like sexual dysfunction, irritability, and emotional blunting.
“MDD is notoriously challenging to manage due to the resistance many patients experience with existing therapies and the significant side effects associated with current medications. Research like this is essential for identifying new solutions. BHV-7000 has shown potential in early studies for better tolerability and effectiveness, for those who struggle with this debilitating disorder.”…